However, levels of adaptive immunity can be utilized to predict protection, as we have previously shown that for Ad26-based Ebola and HIV vaccines, binding antibodies are a strong predictor of protection17,25 and in addition HIV-specific IFNγ cellular immune responses correlated with efficacy in Ad26 HIV–immunized NHPs17. This evidence concerns the gene IFNG and Ebola hemorrhagic fever.